高血压对冠心病患者血管内皮功能影响的研究

目的　探讨高血压对冠心病患者血管内皮功能的影响。方法　通过检测 38例单纯冠心病患者 (A组 )、5 2例冠心病合并高血压病患者 (B组 )、12例健康对照组 (C组 )的肱动脉舒张功能 :反应性充血后血管舒张 (FMD)、含服硝酸甘油后的血管舒张 (NID)及血内皮素 (ET)、一氧化氮 (NO)等指标并进行对比分析。结果　 (1)FMD、ET :A、B组较C组均有显著差异 (均P <0 0 1) ;(2 )NO :B组较C组明显降低 (P >0 0 5 ) ;(3)A、B组间 :FMD、ET、NO均有显著差异 (均P <0 0 5 ) ;(4 )NID在三组间无差异 (P <0 0 5 ) ;(5 )FMD :与NO呈正相关 (r=0 4 3,P <0 0 1) ,与SBP、LDL、ET呈负相关(r =- 0 5 2、- 0 36和 - 0 4 7,均P <0 0 1) ;SBP :与LDL、ET呈正相关 (r =0 2 5和 0 4 2 ,P <0 0 5 ) ,与NO呈负相关 (r<- 0 31,P <0 0 1)。结论　冠心病患者存在显著的内皮依赖性舒张功能障碍 ;高血压病加重冠心病患者的内皮依赖性舒张功能障碍 ;FMD与NO、ET均可作为反映冠心病和高血压病者血管内皮功能的无创指标。     

糖尿病患者内皮tPA、NO储备与血管舒张功能变化

目的　探讨糖尿病患者血管舒张功能和内皮组织纤溶酶原激活物 (tPA)、一氧化氮 (NO)储备释放功能与糖尿病性血管病变的关系。方法　对 15名正常人和 2 3例 2型糖尿病患者 ,采用高频超声方法测定血流介导和硝酸甘油介导的血管舒张功能和颈总动脉内膜厚度 ,以及采用静脉闭塞试验测定tPA和NO储备释放。结果　与正常对照组比较 ,糖尿病组的非内皮依赖性血管舒张功能无显著变化 ,而内皮依赖性血管舒张功能和tPA、NO释放明显低下 (P <0 .0 5或P <0 .0 1) ,颈总动脉内膜增厚 ,但差异无显著性。正常组血tPA水平与NO水平 ,以及tPA释放与NO释放呈显著正相关 ,而糖尿病组收缩压、舒张压均与内皮依赖性血管舒张功能和非内皮依赖性血管舒张功能呈显著负相关。结论　糖尿病患者存在明显的内皮tPA、NO储备释放功能和内皮依赖性舒张功能障碍 ,此与糖尿病性血管病变密切相关     

复方丹参注射液治疗2型糖尿病患者的临床研究

将2型DM患者分为丹参治疗组和对照组;另外选取48名健康人作为健康组.运用无创超声检查技术,观察用药前后颈动脉内-中膜厚度(IMT)及肱动脉内皮依赖性舒张功能(FMD)的变化,同时检测血清一氧化氮(N0)及内皮素-1(ET-1)的浓度水平.结果治疗前DM各组IMT值和血清ET-1水平较健康组明显升高(P＜0.01),FMD值和NO水平却显著下降(P＜0.01),IMT、FMD与NO存在着显著的相关性.治疗4周后,与对照组比较,IMT值和ET-1水平明显降低,FMD和NO水平显著升高.结论复方丹参注射液治疗2型DM患者,可以逆转或延迟颈动脉IMT的进程,改善血管内皮功能.     

2型糖尿病患者血管舒张功能和一氧化氮释放变化及与动脉硬化的关系

目的　探讨 2型糖尿病患者血管舒张功能和一氧化氮释放与糖尿病血管病变的关系。方法　选择 2 0名正常人 (对照组 )和 62例 2型糖尿病患者 (糖尿病组 ) ,并根据患者是否合并冠心病进行分组分析。采用高频超声方法测定反应性充血试验和口服硝酸甘油前后的肱动脉内径变化 ,以反映血管内皮依赖性和非内皮依赖性舒张功能 ,以及静脉闭塞试验测定一氧化氮储备释放 ,同时利用超声方法检测颈总动脉内膜厚度。结果　与对照组比较 ,糖尿病组的非内皮依赖性血管舒张功能无显著变化 (P >0 .0 5 ) ,而内皮依赖性血管舒张功能和内皮一氧化氮释放明显低下 (P<0 .0 5～ 0 .0 1) ,颈总动脉内膜厚度明显增厚 (P <0 .0 1)。糖尿病合并冠心病患者血管内皮依赖性和非内皮依赖性舒张功能均较非合并冠心病患者明显低下。结论　高频超声检测方法能够较好地判断糖尿病患者血管舒张功能。糖尿病患者存在明显的动脉硬化和因一氧化氮释放减少而出现的内皮依赖性舒张功能障碍 ,此与糖尿病性血管病变密切相关     

普伐他汀降脂治疗对血管内皮舒张功能的影响

目的　研究普伐他汀对冠心病高胆固醇血症患者血管内皮依赖性舒张功能的影响。方法　采用高分辨超声技术 ,对 70例冠心病高胆固醇血症患者降脂前后和 70例对照者的血管内皮依赖性舒张功能进行检测。结果　高胆固醇血症组肱动脉血流介导性舒张较正常组明显减弱(P <0 0 0 1 ) ,而二组对硝酸甘油的反应无显著性差异 (P =0 49)。 70例冠心病高胆固醇血症患者服用普伐他汀 1 0mg治疗 (3 8± 0 8)月后 ,血浆总胆固醇从 (6 31± 0 70 )mmol/L降至 (5 0 6± 0 63)mmol/L ,同时肱动脉内皮依赖性舒张较治疗前明显改善 (P <0 0 0 1 ) ,而治疗前后肱动脉对硝酸甘油的反应无显著性改变。结论　冠心病高胆固醇血症患者存在血管内皮依赖性舒张功能障碍 ,经普伐他汀降胆固醇治疗后 ,受损的血管内皮依赖性舒张功能得到明显改善     

维生素C对吸烟者慢性内皮功能失调的作用

观察抗氧化剂治疗能否改善吸烟者的内皮功能 ,将 4 6例健康男性吸烟者随机分为维生素C组 (n =2 3)和安慰剂组 (n=2 3)。维生素C组口服维生素C 1g/d ,连续 30天 ,服药期间不中断吸烟。选择 11例健康男性非吸烟者作为对照组。于基础状态及治疗后 30天测定受试者血浆抗坏血酸浓度及肱动脉内皮功能。结果发现 ,与非吸烟者比较 ,健康男性吸烟者肱动脉内皮依赖性血管舒张下降 ,且血浆抗坏血酸浓度降低 (P <0 .0 1)。经维生素C治疗后 ,维生素C组血浆抗坏血酸水平升高 (P <0 .0 1) ,内皮依赖性血管舒张增加 (P <0 .0 1) ,而安慰剂组抗坏血酸水平及内皮依赖性血管舒张均无明显改变。提示健康吸烟者存在血管内皮功能失调 ,抗氧化剂维生素C治疗能够改善吸烟者内皮舒张功能。     

别嘌呤醇对冠心病患者内皮功能及心功能的影响

目的 :观察别嘌呤醇对冠心病并高尿酸血症患者内皮依赖性血管舒张功能及心功能的影响。方法 :选择经冠状动脉造影确诊为冠心病的患者 71例 ,对其中 46例冠心病并高尿酸血症患者随机分成两组 (各组n =2 3 ) ,别嘌呤醇组给予别嘌呤醇 0 4g/d ,安慰剂组给予谷维素 60mg/d ;另 2 5例冠心病尿酸正常患者为尿酸正常组 ,给予别嘌呤醇 0 4g/d ,均观察 4周 ,采用高精度血管超声技术检测肱动脉内皮依赖性血管舒张功能及心脏彩色多普勒超声测定左心室舒张功能指标 :舒张早期峰值速度 /舒张晚期峰值速度 (E/A)、峰减速时间、峰减速率 ;收缩功能指标 :左心室射血分数、左心室短轴内径缩短率 ,同时测定血清尿酸、血浆丙二醛水平。结果 :仅别嘌呤醇组治疗后较治疗前比较血清尿酸、血浆丙二醛水平降低 ,肱动脉内皮依赖性血管舒张功能增强 ,均有极显著性差异 (P <0 0 1) ,E/A、峰减速率增加 ,均有显著性差异 (P <0 0 5及P <0 0 1) ,左心室射血分数、左心室短轴内径缩短率有增加趋势 (P >0 0 5 ) ,但未达到统计学显著性。Δ血清尿酸与Δ肱动脉内皮依赖性血管舒张功能、ΔE/A、Δ峰减速率负相关 ,相关系数分别为 -0 47、-0 3 9、-0 41(P <0 0 5 ) ,与Δ射血分数、Δ短轴内径缩短率相关系数分别为 -0 2 9、-0 2     

保利尔胶囊对冠心病患者血管内皮功能和C-反应蛋白水平的影响

目的 观察保利尔胶囊对冠心病患者血管内皮功能和C-反应蛋白(CRP)的影响.方法 选择冠心病患者87例,随机分为治疗组和对照组,对照组采用常规西药治疗;治疗组在常规西药治疗的基础上加用保利尔胶囊4粒/次,3次/日,服用1个月.观察两组治疗前后血管内皮依赖性舒张功能(EDD)、血浆内皮素-1(ET-1)、一氧化氮(NO)和CRP水平等指标的变化.结果 治疗后,治疗组ET-1均明显下降(P＜0.05),NO明显升高(P＜0.05),但治疗组ET-1、NO较对照组变化更明显(P＜0.05).治疗后的肱动脉EDD,治疗组为(9.67±3.10)％较对照组(4.32±2.78)％明显改善(P＜0.05);而肱动脉内皮非依赖性血管舒张功能(NMD)也得到明显改善(P＜0.05).结论 保利尔胶囊可使血浆ET-1水平明显下降,NO水平明显升高,EDD、NMD明显改善,CRP明显降低,提示保利尔胶囊有显著保护血管内皮功能、抑制炎症和改善临床症状的作用.     

2型糖尿病患者血浆护骨素浓度与内皮依赖性血管舒张功能关系的研究

目的探讨T2DM患者血浆护骨素(OPG)浓度与内皮依赖性血管舒张功能的关系。方法选取T2DM患者(T2DM组)154例和健康对照(NC)者46名,分别测定其血浆OPG浓度,并采用高分辨血管外超声法检测肱动脉血流介导的内皮依赖性血管舒张功能和硝酸甘油介导的非内皮依赖性血管舒张功能。结果 T2DM组血流介导的内皮依赖性血管舒张功能为(3.56±0.64)%,低于NC组(5.32±0.55)%(P<0.01)。多元回归分析显示,内皮依赖性血管舒张功能、24hUAlb均与血浆OPG水平相关。Pearson相关分析显示,OPG浓度与内皮依赖性血管舒张功能呈负相关(r=-0.284,P=0.000)。结论血浆OPG水平在T2DM患者中升高,其水平与内皮依赖性血管舒张功能呈负相关。     

罗格列酮对2型糖尿病大鼠主动脉内皮依赖性血管舒张功能的影响

目的观察2型糖尿病（T2DM）大鼠胸主动脉内皮依赖性血管舒张功能和一氧化氮（NO）、一氧化氮合酶（eNOS）的变化及罗格列酮（RSG）治疗对其内皮功能的影响。方法SD大鼠经高糖高脂喂养6周后予小剂量链脲佐菌素腹腔注射建立T2DM大鼠模型，糖尿病大鼠又分为对照（DM）组和RSG治疗组，RSG组用RSG干预8周，另选正常大鼠为正常对照（NC）组。实验终止时用正常葡萄糖高胰岛素钳夹技术的葡萄糖输注率（GIR）评价胰岛素抵抗，观察大鼠离体主动脉内皮依赖性血管舒张反应和主动脉NO、eNOS的变化。结果T2DM大鼠GIR、胸主动脉内皮依赖性血管舒张反应、主动脉NO含量及eNOS阳性表达较NC组显著降低（P〈0、01），RSG治疗后上述指标均显著升高（P〈0．05）。结论T2DM大鼠存在内皮依赖性血管舒张功能紊乱，RSG治疗可改善内皮功能，增强NO水平和eNOS的活性。     

阿托伐他汀对冠心病患者的血管舒张功能的影响

目的观察阿托伐他汀对冠心病患者血管舒张功能的作用。方法将入选60例冠心病并高胆固醇血症患者随机分为阿托伐他汀治疗组(A组)和对照组(B组)。分别测定血清胆固醇、三酰甘油、低密度脂蛋白胆固醇和高密度脂蛋白胆固醇。并应用高分辨率超声技术,检测治疗前、后两组肱动脉血流介导和硝酸甘油介导的舒张功能。结果治疗前,冠心病并高胆固醇血症患者肱动脉血流介导和硝酸甘油介导的舒张功能均低于健康对照组(P<0.01)。经阿托伐他汀治疗6个月后A组血浆总胆固醇、三酰甘油和低密度脂蛋白胆固醇显著降低(P<0.01),高密度脂蛋白胆固醇显著升高(P<0.01)。随着血脂的改善,肱动脉内皮依赖性血管舒张功能显著提高(P<0.01),但硝酸甘油介导的血管舒张功能未见改善(P>0.05)。结论冠心病并高胆固醇血症患者存在内皮依赖性血管舒张功能障碍,经阿托伐他汀调脂治疗后,受损的内皮依赖性血管舒张功能得到明显改善。     

高尿酸血症对血管内皮功能影响的观察

目的　观察高尿酸血症对血管内皮功能的影响。方法　对 30例高尿酸血症男性患者和 30例正常男性采用高分辨超声技术检测血流介导和硝酸甘油介导的肱动脉舒张功能 ,并测定血浆内皮素和一氧化氮。结果　 (1)高尿酸血症患者血流介导的肱动脉舒张较正常组明显减弱 (P <0 0 1) ,而两组对硝酸甘油的血管舒张反应差异无显著性 (P >0 0 5 ) ;(2 )高尿酸血症患者血浆内皮素水平显著高于正常组 (P <0 0 1) ;一氧化氮水平显著低于正常组 (P <0 0 5 )。结论　高尿酸血症患者内皮依赖性血管舒张功能明显受损 ,血管内皮功能失调可能是高尿酸血症致动脉粥样硬化的一个重要机制。     

Low Levels of Serum Soluble Receptors for Advanced Glycation End Products,Biomarkers for Disease State: Myth or Reality

Advanced glycation end products (AGEs) interact with the receptor for AGEs (RAGE) on the membrane and induce deleterious effects via activation of nuclear factor kappa-B, and increased oxidative stress and inflammatory mediators. AGEs also combine with circulating soluble receptors (endogenous secretory RAGE [esRAGE] and soluble receptor for RAGE [sRAGE]) and sequester RAGE ligands and act as a cytoprotective agent. esRAGE is secreted from the cells and is a spliced variant of RAGE. The sRAGE on the other hand is proteolytically cleaved from cell surface receptor via matrix metalloproteinase (MMPs). sRAGE is elevated in type 1 and type 2 diabetes and in patients with decreased renal function. Serum levels of sRAGE are reduced in diseases including coronary artery disease, atherosclerosis, essential hypertension, chronic obstructive lung disease, heart failure, and hypercholesterolemia. Serum levels of AGEs are elevated in patients with coronary artery disease and atherosclerosis. However, the increases in serum AGEs are very high in patients with diabetes and renal disease. There is a positive correlation between serum levels of AGEs and RAGE and sRAGE. The elevated levels of sRAGE in patients with diabetes and impaired renal function may be due to increased levels of MMPs. AGEs increase in the expression and production of MMPs, which would increase the cleavage of sRAGE from cell surface. In conclusion, low level of serum sRAGE is a good biomarker for disease other than diabetes and renal disease. A unified formula that takes into consideration of AGEs, sRAGE, and esRAGE such as AGE/sRAGE or AGEs/esRAGE would be better biomarker than sRAGE or esRAGE for all AGE-RAGE–associated diseases including diabetes and renal disease.     

Enhanced coronary calcification determined by electron beam CT is strongly related to endothelial dysfunction in patients with suspected coronary artery disease

BACKGROUND: Coronary artery calcification determined by electron beam CT (EBCT) is strongly associated with total plaque burden but is not related to systemic vascular inflammation.Aims: We sought to test the hypothesis that enhanced coronary artery calcification, a marker of atherosclerosis and plaque burden, was related to endothelial dysfunction in patients with suspected coronary artery disease (CAD). METHODS AND RESULTS: One hundred twenty-four subjects with suspected CAD were enrolled. Coronary artery calcification was detected by EBCT. A noninvasive method of brachial ultrasound was used to measure endothelium-dependent flow-mediated vasodilation (FMD) and endothelium-independent nitroglycerin-mediated vasodilation (NMD). Serum high-sensitivity C-reactive protein (hsCRP) and monocyte chemoattractant protein-1 (MCP-1) levels were also determined. Of the 124 patients, the calcium scores ranged from 0 to 4,394. All subjects were classified into three groups according to coronary calcium scores: group 1, score 0 (n = 26); group 2, scores 1 to 199 (n = 50); group 3, scores > or = 200 (n = 48). There was an inverse association between the degree of coronary artery calcification and the endothelium-dependent FMD in the three groups (6.9 +/- 0.6% vs 5.3 +/- 0.3% vs 3.7 +/- 0.3%, respectively; p < 0.001) but not the endothelium-independent NMD. Besides, no significant difference in serum levels of hsCRP and MCP-1 were found among the three groups. However, both the serum levels of hsCRP and MCP-1 were correlated significantly with endothelium-dependent FMD (r = - 0.211, p = 0.019; and r = - 0.188, p = 0.037, respectively). By multivariate analysis, enhanced coronary calcification was a strong independent predictor of endothelial dysfunction (p < 0.001). CONCLUSION: Enhanced coronary artery calcification strongly predicted endothelial dysfunction in patients with suspected CAD. Also, serum levels of hsCRP and MCP-1 were significantly correlated with endothelial function. These findings suggested that both calcium deposition and inflammation were involved in endothelial dysfunction.     

Increased basal levels of plasma nitric oxide in Type 2 diabetic subjects. Relationship to microvascular complications

To assess the underlying mechanisms of decreased endothelial function and advanced vascular complications in patients with Type 2 diabetes, we determined basal levels of plasma nitric oxide (NO(x): NO(2)(-) and NO(3)(-)) using a newly developed high-performance liquid chromatography (HPLC)-Griess method in hospitalized 129 diabetic and 76 nondiabetic subjects, and examined their clinical characteristics. Serum lipid peroxide and advanced glycation end products (AGEs) as markers of oxidative stress were also measured, and intima-media thickness (IMT) of the carotid artery was evaluated as a marker of atherosclerosis. In diabetic subjects, microvascular complications were newly evaluated during their admission. There were no differences in age or sex between the diabetic and nondiabetic subjects. Although there was no difference in basal plasma NO(2)(-) levels between the two groups, the basal levels of plasma NO(3)(-) in diabetic subjects were significantly higher than those in nondiabetic subjects. Plasma NO(x) levels in neither diabetic nor nondiabetic subjects correlated with serum lipids, HbA1c, or IMT. In diabetic subjects, plasma NO(3)(-) levels were related not only to the presence of hypertension but also to advanced microvascular complications. Moreover, plasma NO(3)(-) levels were positively correlated with both serum lipid peroxide and AGEs. Multiple regression analysis revealed that serum AGEs level was strongly associated with plasma NO(3)(-) level. Thus, the findings are consistent with the hypothesis that decreased endothelium-dependent vasodilation in diabetic subjects is associated with the impaired action of NO secondary to its inactivation resulting from increased oxidative stress, rather than decreased NO production from vascular endothelium, and that abnormal NO metabolism is related to advanced diabetic microvascular complications.     

Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes.

Recent studies have suggested that hypercholesterolemia is associated with endothelial dysfunction. In patients with type 2 diabetes mellitus, dyslipidemia is mainly characterized by hypertriglyceridemia, low high density lipoprotein, and a preponderance of small dense low density lipoprotein (LDL) particles. We have examined the relationships among LDL subfractions, the susceptibility of LDL to oxidation in vitro, and endothelial function in type 2 diabetes mellitus. LDL subfractions were measured by density gradient ultracentrifugation. The susceptibility of LDL to oxidation was determined by measuring the kinetics of conjugated dienes formation during copper-mediated oxidation of LDL. Endothelium-dependent and independent vasodilation of the brachial artery were assessed by high resolution vascular ultrasound. Diabetic patients had a higher concentration of small dense LDL-III than matched controls (P < 0.01). The lag phase of conjugated dienes formation was shorter in the diabetic patients (P < 0.05), and the rate of LDL oxidation was faster (P < 0.05). Both endothelium-dependent (P < 0.01) and independent dilation of the brachial artery (P < 0.01) were impaired in the diabetic patients. On multivariate analysis, the rate of oxidation and LDL-III concentration accounted for 12% and 6%, respectively, of the variation in endothelium-dependent vasodilation (adjusted r2 = 0.18; P < 0.05), whereas LDL-III concentration and the maximum amount of conjugated dienes formed accounted for 27% and 5%, respectively, of the variation in endothelium-independent vasodilation (adjusted r2 = 0.32; P < 0.01) in the diabetic patients. In conclusion, endothelial and smooth muscle cell dysfunction in type 2 diabetes were related to abnormalities in LDL subfractions and in LDL oxidation.     

单纯收缩期高血压患者血管内皮功能与左心室肥厚的关系

目的探讨单纯收缩期高血压患者血流介导的血管舒张功能(FMD)与左心室肥厚(LVH)的关系。方法选择单纯收缩期高血压患者200例,根据左心室质量指数分为:LVH组73例和非LVH组127例,同期选择年龄匹配的健康体检者50例作为对照组,采用超声技术测定FMD,ELISA法检测外周血清晚期糖基化终末产物(AGEs)和内皮素1,Griess法测定外周血NO含量。结果与非LVH组和对照组比较,LVH组FMD明显降低,AGEs和内皮素1均明显升高(P0.01)。左心室质量指数与AGEs和内皮素1呈显著正相关(r=0.639,P=0.015;r=0.428,P=0.036),与FMD和NO呈显著负相关(r=-0.718,P=0.003;r=-0.337,P=0.041);FMD和AGEs为LVH的独立危险因素(P=0.027,P=0.035);随着FMD降低、AGEs增加,LVH发病的危险性明显增加。结论血管内皮功能减退和大动脉硬化是单纯收缩期高血压患者LVH的独立危险因素。     

不同糖耐量冠心病患者血清内脂素水平与冠状动脉狭窄程度的关系

目的 比较血清内脂素(visfatin)在不同糖耐量水平冠心病患者和正常个体中的表达情况,评价血清内脂素水平与冠状动脉狭窄程度的关系.方法 经冠状动脉造影确诊冠心病患者85例,按1999年世界卫生组织糖尿病诊断标准分为冠心病正常糖耐量组(CHD)34例、冠心病合并糖调节异常组(CIG)25例、冠心病合并2型糖尿病组(CDM)26例,选择健康志愿者30名(冠状动脉CT血管造影阴性)作为正常对照组(CON).检测受试者人体测量学指标及糖、脂代谢指标;应用Gemini冠状动脉评分系统对冠状动脉狭窄程度进行评估;用SPSS 12.0统计软件包进行统计学分析.结果 与CON组比较,CHD、CIG及CDM组血清内脂素水平均显著增高(均P<0.05);与CHD组相比较,CIG和CDM组血清内脂素水平均显著增高(均P<0.05);内脂素水平与Gesini冠状动脉病变积分呈正相关(r=0.669,P<0.01);内脂素与腰围、腰臀比、甘油三酯呈正相关(r=0.200,P=0.032;r=0.185,P=0.047;r=0.321,P<0.01),与高密度脂蛋白胆固醇(HDL-C)呈负相关(r-0.354,P<0.01),多元回归分析显示,腰围、甘油三酯水平为影响内脂素水平的主要因素.结论 (1)血清内脂素水平较好地反映冠状动脉病变的严重程度,检测内脂素水平有助于冠心病的早期诊断.(2)在合并2型糖尿病及糖调节异常的冠心病患者中,血清内脂素表达显著增高,与临床糖尿病患者更重的冠状动脉病变相符合.(3)腰围、甘油三酯水平为影响血清内脂素水平的主要因素,提示内脂素水平与腹型肥胖密切相关.

Abstract：

Objective To investigate the relationship between serum visfatin level and coronary artery stenosis.Methods Based on coronary angiography,85 patients were diagnosed as coronary heart disease.According to oral glucose tolerance test,these patients were divided into 3 groups,34 patients with normal glucose tolerance(CHD group),25 with impaired glucose regulation(CIG group),and 26 with type 2 diabetes mellitus(CDM group).30 non-comary heart disease subjects with normal glucose tolerance were selected as the control group(CON group),and they underwent coronary CT angiography scan and were confirmed coronary disease-free.Blood pressure,body mass index(BMI),waist circumference(WC),waist hip ratio(WHR),fasting plasma glucose(FPG),blood lipid analysis,fasting insulin,and HbA1C were determined.Serum visfatin concentration was assayed and the status of coronary artery was assessed.Coronary artery stenosis was screened by coronary interventional angiography and assessed by Gemini scoring system in CHD,CIG,and CDM groups.Results Compared with control group,serum visfatin in CHD,CIG,and CDM groups were significantly higher(all P<0.05).Compared with CHD group,serum visfatin in CIG and CDM groups were significantly higher(all P<0.05).The correlation analysis showed that serum visfatin level was positively correlated with the involved branches of coronary arteries(r=0.807,P<0.01),serum visfatin level was positively related with Gensini coronary artery score(r=0.669,P<0.01).Visfatin was also positively correlated with WC,WHR,triglyceride(TG,r=0.200,P=0.032,r=0.185,P=0.047,r=0.321,P<0.01),while high density lipoprotein cholesterol(HDL-C)was negatively correlated with visfatin(r=-0.354,P<0.01).Multiple regression analysis showed that senlm hvel of TG and WC were the main influencing factors of visfatin.Conclusion (1)The level of serum visfatin may reflect the severity of coronary artery stenosis,detection of visfatin helps to make early diagnosis of CHD.(2)The raised serum level of visfatin in comary heart disease patients with imparied glucose tolerance is consistent with clinical evidence that diabetic patients have more severe coronary diseases.(3)WC and serum TG are main inilucencing factors,suggesting that visfatin is correlated with abdominal obesity.